Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Guillain-Barre syndrome
ADR ID BADD_A01890
ADR Hierarchy
10      Immune system disorders
10.04      Autoimmune disorders
10.04.10      Nervous system autoimmune disorders
10.04.10.005      Guillain-Barre syndrome
11      Infections and infestations
11.07      Ancillary infectious topics
11.07.01      Inflammatory disorders following infection
11.07.01.001      Guillain-Barre syndrome
17      Nervous system disorders
17.09      Peripheral neuropathies
17.09.01      Acute polyneuropathies
17.09.01.001      Guillain-Barre syndrome
Description A disorder characterized by the body's immune system attacking the peripheral nervous system causing ascending paralysis. [CTCAE] An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314) [MeSH]
MedDRA Code 10018767
MeSH ID D020275
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Acute infective polyneuritis | Guillain Barre syndrome | Guillain-Barre syndrome | Syndrome Guillain-Barre | Acute inflammatory demyelinating polyradiculopathy | Acute inflammatory demyelinating polyradiculoneuropathy | AIDP | Guillain-Barre Syndrome | Guillain Barre Syndrome | Syndrome, Guillain-Barre | Guillain-Barré Syndrome | Guillain Barré Syndrome | Guillain-Barré Syndromes | Syndrome, Guillain-Barré | Syndromes, Guillain-Barré | Acute Infectious Polyneuritis | Infectious Polyneuritis, Acute | Polyneuritis, Acute Infectious | Guillaine-Barre Syndrome | Guillaine Barre Syndrome | Syndrome, Guillaine-Barre | Acute Autoimmune Neuropathy | Acute Autoimmune Neuropathies | Autoimmune Neuropathies, Acute | Autoimmune Neuropathy, Acute | Neuropathies, Acute Autoimmune | Neuropathy, Acute Autoimmune | Landry-Guillain-Barre Syndrome | Landry Guillain Barre Syndrome | Syndrome, Landry-Guillain-Barre | Acute Inflammatory Demyelinating Polyneuropathy | Inflammatory Polyneuropathy Acute | Polyneuropathy Acute, Inflammatory | Acute Inflammatory Demyelinating Polyradiculoneuropathy | Acute Inflammatory Polyneuropathy | Acute Inflammatory Polyneuropathies | Inflammatory Polyneuropathies, Acute | Inflammatory Polyneuropathy, Acute | Polyneuropathies, Acute Inflammatory | Polyradiculoneuropathy, Acute Inflammatory | Acute Inflammatory Polyradiculoneuropathies | Inflammatory Polyradiculoneuropathies, Acute | Polyradiculoneuropathies, Acute Inflammatory | Polyneuropathy, Inflammatory Demyelinating, Acute | Demyelinating Polyradiculoneuropathy, Acute Inflammatory | Polyneuropathy, Acute Inflammatory | Polyradiculoneuropathy, Acute Inflammatory Demyelinating | Inflammatory Demyelinating Polyradiculoneuropathy, Acute | Acute Inflammatory Polyradiculoneuropathy | Guillain-Barre Syndrome, Familial | Familial Guillain-Barre Syndrome | Familial Guillain-Barre Syndromes | Guillain Barre Syndrome, Familial | Guillain-Barre Syndromes, Familial | Syndrome, Familial Guillain-Barre | Syndromes, Familial Guillain-Barre
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02070Streptokinase--
BADD_D02093Sulfasalazine--
BADD_D02100Sunitinib0.000392%
BADD_D02105Tacrolimus0.003564%
BADD_D02154Tenofovir0.002908%
BADD_D02236Tofacitinib0.001085%
BADD_D02254Tramadol0.000014%
BADD_D02344Vemurafenib0.000112%
BADD_D02346Venlafaxine--
BADD_D02369Voriconazole--
BADD_D02370Vorinostat--
BADD_D02375Water--
BADD_D02482Acalabrutinib0.000112%
BADD_D02577Oseltamivir acid0.000372%
The 3th Page    First    Pre   3    Total 3 Pages